Article Information
History
- December 11, 2021.
Article Versions
- Version 1 (December 8, 2021 - 06:50).
- Version 2 (December 8, 2021 - 15:27).
- You are currently viewing Version 3 of this article (December 11, 2021 - 15:19).
- View Version 4, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Alexander Wilhelm1,*,
- Marek Widera1,*,
- Katharina Grikscheit1,
- Tuna Toptan1,
- Barbara Schenk1,
- Christiane Pallas1,
- Melinda Metzler1,
- Niko Kohmer1,
- Sebastian Hoehl1,
- Fabian A. Helfritz2,
- Timo Wolf3,
- Udo Goetsch4 and
- Sandra Ciesek1,5,6,#
- 1Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany
- 2Bürgerhospital Frankfurt, Nibelungenallee 37-41, 60318 Frankfurt am Main, Germany
- 3Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany
- 4Health Protection Authority of the City of Frankfurt am Main, 60313 Frankfurt am Main, Germany
- 5German Center for Infection Research (DZIF), 38124 Braunschweig, Germany
- 6Branch Translational Medicine and Pharmacology, Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), 60596 Frankfurt am Main, Germany
- ↵#Corresponding author: Sandra Ciesek M.D. (sandra.ciesek{at}kgu.de)
↵* contributed equally
Posted December 11, 2021.
Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and Monoclonal Antibodies
